Are you a scientist, inventor, drug developer or investor involved in the development of innovative medicines (including technology platforms, ATMPs, and orphan drugs)? Is your objective to generate (in-vivo or clinical) proof-of-concept data to prepare for fundraising? Or do you need to get a better understanding of the key challenges/choices in the non-clinical, quality and/or clinical development of your asset(s)? If you are searching for answers to any of the above questions, or if you have any other question related to developing innovative medicines, then don’t hesitate to get in touch with us to understand how the team at TIC-T can help. TIC-T offers extensive experience in optimising the development of innovative medicines through integration of non-clinical, quality and clinical development expertise in the context of the appropriate regulatory framework, taking into consideration the company’s business strategy. At TIC-T we recognize the importance of: • Connecting individuals/experts at an early stage; • Leveraging the available data/information, and • Creating a structured framework within the company to allow successful and (cost-)efficient execution. What makes us unique is: (1) our shared hands-on experience in the translation and development of several innovative medicinal products/ATMPs/orphan drugs, (2) our understanding of the importance of context, and (3) the power of personal connection and teams in bringing these promising medicines to patients. Unfortunately, blueprints for a successful development of these type of products do not exist due to the innovative nature of the underlying science and the (definition of the) product/technology platform. We are experienced in finding innovative and out-of-the box solutions for the optimal route to market. We use a fail-fast methodology to: (1) avoid exposing patients to investigational products that should have been terminated early and (2) minimize any unnecessary spending.